ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery
1. ICON's Q2 revenue of $2.02 billion exceeded expectations. 2. Adjusted earnings of $3.26 per share surpassed consensus estimates. 3. The company raised its 2025 sales guidance to $7.85 billion-$8.15 billion. 4. A new $500 million expansion in share buybacks increases total to $1 billion. 5. Analysts noted strong bookings despite ongoing challenges in the clinical environment.